Lung Scintigraphy in COPD by Mortensen, Jann & Berg, Ronan M G
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Lung Scintigraphy in COPD
Mortensen, Jann; Berg, Ronan M G
Published in:
Seminars in Nuclear Medicine
DOI:
10.1053/j.semnuclmed.2018.10.010
Publication date:
2019
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY-NC-ND
Citation for published version (APA):
Mortensen, J., & Berg, R. M. G. (2019). Lung Scintigraphy in COPD. Seminars in Nuclear Medicine, 49(1), 16-
21. https://doi.org/10.1053/j.semnuclmed.2018.10.010
Download date: 03. Feb. 2020
Lung Scintigraphy in COPD
Jann Mortensen, MD, DMSc,*,†,z and Ronan M.G. Berg, MD, PhD*,x
Ventilation-perfusion scintigraphy is a functional imaging biomarker that has the potential of*Department of Clinic
talet, University H
yDepartment of Clinic
Denmark.
zDepartment of Medic
xFaculty of Life Scie
Pontypridd, United
Disclosure: The author
Address reprint reque
Clinical Physiolo
University Hospit
Copenhagen Est, D
16 https://doi.org/
0001-2998/©
(http://creativecaptivating the heterogeneity of chronic obstructive pulmonary disease (COPD). It specifi-
cally images the distribution of ventilation and perfusion within the lungs, which is a critical
pathophysiological component of COPD. The extent of ventilation defects and ventilation
inhomogeneity, as well as the ventilation-perfusion ratio distribution thus correlate with
severity of disease. Furthermore, specific scintigraphic patterns, such as the “stripe sign”
may detect centrilobular emphysematous lesions with a higher sensitivity than other imag-
ing techniques. Although ventilation-perfusion scintigraphy may conceivably detect COPD
before any specific changes can be detected by spirometry or high-resolution CT, it is cur-
rently mostly used in the workup of lung volume reduction treatment, and for diagnosing
various complications and comorbidities of COPD when combined with low-dose CT.
Semin Nucl Med 49:16-21 © 2018 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY-NC-ND license.
(http://creativecommons.org/licenses/by-nc-nd/4.0/)Introduction
Chronic obstructive pulmonary disease (COPD) is causedby a mixture of small airway disease (obstructive bronchi-
olitis) and parenchymal destruction (emphysema), the relative
contribution of which varies from person to person.1 The diag-
nosis is based on relevant symptoms, particle/gas exposure
(most often tobacco smoke), and spirometric ﬁndings of air-
ﬂow limitation that is not fully reversible.1 COPD is classiﬁed
as GOLD 1-4 according to the reduction in ventilatory capac-
ity, as evaluated spirometrically by the forced expiratory vol-
ume in 1 second (FEV1). Unfortunately, FEV1 and other
spirometric indices are largely inadequate for describing the
heterogeneity of COPD. First, spirometric indices are typically
not affected during the very early stages of disease, and second,
they only vaguely reﬂect the severity of symptoms, quality of
life, and exercise performance during more severe COPD.2al Physiology, Nuclear Medicine and PET, Rigshospi-
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which may better explain the variation in individual disease
burden in COPD patients,2 clear alternatives have not yet
emerged. In the present review, ventilation-perfusion (V/Q)
scintigraphy is highlighted as a promising functional imaging
biomarker for phenotyping COPD, detecting early COPD, and
for evaluating speciﬁc treatment responses.Pathophysiology of COPD
COPD involves the destruction of alveolar septa and respiratory
bronchioles and inﬂammation with the invasion of various
immune cells, notably neutrocytes, into the bronchial walls and
lumen.3,4 While the former leads to a loss of parenchymal elas-
tic recoil, and thus hyperinﬂation and peripheral airway
obstruction, inﬂammation causes obstruction of both large and
small airways, both due to excess mucus within the airways as
well as by triggering bronchoconstriction.4,5 Furthermore, neu-
trocyte degranulation products, such as elastases, contribute to
the loss of pulmonary elastic recoil.5 Accordingly, neutrophilic
inﬂammation in the lungs as visualized by 18F-FDG PET/CT
has been found to be greatest in lung regions with emphysema
predominance, and to correlate with clinical measures of disease
severity in the patients with stable COPD.6
The abovementioned changes render the distribution of
ventilation more inhomogeneous, as observed during all
grades of COPD. The degree is mild in the early stages of dis-
ease where inﬂammation and tissue destruction areaccess article under the CC BY-NC-ND license.
Lung Scintigraphy in COPD 17principally present in peripheral lung zones, while more
severe inhomogeneity is evident in later and higher COPD
stages, where the more central bronchioles and bronchi are
also involved. Indeed, the initial changes probably take place
in the small airways, as smoking even in the absence of clini-
cal COPD leads to a notable inhomogeneous distribution of
albumin radioaerosol deposition in the lungs,7 which is char-
acteristic of low ﬂow rates in the small airways.8
Although hypoxic vasoconstriction ensues in less ventilated
regions during all stages of COPD, the distribution of ventila-
tion and perfusion throughout the lungs becomes unequal,
thus impairing pulmonary gas exchange.9 Changes in pulmo-
nary vascular function triggered by the direct effects of parti-
cle/gas irritants or the associated inﬂammatory pathways
contribute to this, and appear to predominate during lower
COPD-stages, and furthermore may precede any detectable
changes in ventilation in patients prone to develop COPD.10,11
High-resolution CT (HRCT) is the method of choice for
visualizing and quantifying emphysema, and classifying it
morphologically into centrilobar, panlobular, paraseptal, and
irregular airspace enlargement subtypes.12 However, given
the pertinence of the distribution of ventilation and perfusion
to the pathophysiology of COPD, V/Q scintigraphy may
unveil several aspects of disease that are not detected by
HRCT which will be outlined below.Ventilation and Perfusion
Scintigraphic Findings in COPD
Both ventilation and perfusion inhomogeneity can be
assessed separately or combined by planar or tomographic
(SPECT) V/Q scintigraphy (Fig. 1).13 While perfusion
scintigraphy is performed with [99mTc] macroaggregated
albumin, micron-sized, and submicron-sized aerosols
(99mTc-labeled DTPA and 99mTc-labeled clusters of carbon
particles [Technegas], respectively) or inert radioactive gases
(133Xe and 81mKr) may be used for ventilation scintigraphy.
The quality and information gained from ventilation scintig-
raphy depends critically on the tracer. Hence aerosol tracers
tend to deposit and create “hot spots” in the central airways
when airway resistance is increased. This is more pro-
nounced for the micron-sized DTPA aerosol than for Techne-
gas, as the latter may be considered a “pseudogas,”14 but in
severe emphysema ventilation scans that are representative
of the actual physiological distribution of ventilation are
nonetheless best achieved by the use of inert gas tracers.15 In
head-to-head comparisons in severe COPD, 81mKr thus pen-
etrates further into the peripheral airways than Technegas
while “hot spots” are also avoided (Fig. 2).15
The results and interpretation of a ventilation scan in the
COPD patient depend not only on the tracer of choice, but
also on the imaging technique. Hence, the severity and extent
of ventilation defects are detected more accurately by SPECT
(Fig. 2), and furthermore correlate more closely with signs of
airway obstruction, hyperinﬂation, and emphysema as evalu-
ated by lung function testing than when based on planarimaging.16,17 Formalized SPECT-based assessments of
COPD-associated ventilatory disturbances have furthermore
been reported to correlate with severity of patient-reported
symptoms and the extent of emphysema evaluated by
HRCT.18,19 Indeed, the extent of ventilation inhomogeneity
increases with severity of COPD.19,20
When conducted as SPECT, the perfusion scan may
exhibit the so-called “stripe sign,” which is a central reduc-
tion in perfusion with preserved function peripherally in
lung regions with centrilobular emphysema (Fig. 3).16 In
patients with severe COPD, many lung areas with the stripe
sign concurrently show signs of centrilobular emphysema on
HRCT, but in up to 15% of the areas, no speciﬁc changes
can be detected using the latter.16,21 If the SPECT is per-
formed at breath-hold, the resolution furthermore increases,
and the majority of patients will exhibit more extended per-
fusion defects than can be detected on CT.22
When using inert gases as ventilation tracers, the stripe
sign is also evident on the ventilation scan, but when using
Technegas, some areas may be stripe-sign positive on perfu-
sion SPECT but negative on ventilation SPECT, because
Technegas tends to deposit in the central airways (Fig. 2).22
In contrast, the stripe sign is never observed in patients with-
out COPD,16,21 thus indicating that its presence signiﬁes the
presence of centrilobular emphysema, and since it may occur
without any changes on HRCT, that V/Q SPECT is more sen-
sitive for detecting early or mild emphysematous changes
than HRCT.
Due to the critical importance of the distribution of venti-
lation relative to perfusion in the pathophysiology of COPD
as outlined above, some SPECT-based studies have speciﬁ-
cally assessed the distribution of the V/Q ratio and related
indices in the lungs of COPD patients, and automated meth-
ods for doing this have been developed.15,23 Studies have
thus shown that COPD is associated with a very inhomoge-
neous distribution of the V/Q ratio throughout the lungs, a
pattern that worsens with each GOLD category, and corre-
lates with the impairment of pulmonary gas exchange deter-
mined by arterial blood gases.23 This approach furthermore
appears to be more sensitive at detecting emphysematous
lung areas than compared to HRCT.23
Together, the available studies thus indicate that both the
visually based and the more objective automatic approaches
of lung scintigraphy have prospects for early detection and
phenotyping of COPD, particularly when using SPECT
rather than planar scans, while also using inert gases or Tech-
negas rather than aerosols as ventilation tracers.Early Detection of COPD
As outlined above, the early pathophysiological events in
COPD involve changes in pulmonary vascular function and
structural changes in the small airways, neither of which are
detected by spirometry or HRCT. Accordingly, studies of
tobacco smoke-induced emphysema in mice have shown
that the regional distribution of ventilation and perfusion
assessed by SPECT is rendered more inhomogeneous in areas
Figure 1 V/Q SPECT/CT in COPD with and without emphysema and in a healthy volunteer. (A) V/Q SPECT/CT with mildly inhomogeneous
ventilation and perfusion, and normal low dose CT ﬁndings in a middle-aged healthy volunteer with normal lung function. (B) Mismatch in
mixed emphysema and ﬁbrosis. Abnormal V/Q SPECT/CT with ventilation to the periphery and perfusion to the central part of the lobes.
Right/left lung distribution of perfusion: 50/50%; ventilation: 64/36%. Patient with restriction and severely reduced DLco. HRCT shows exten-
sive paraseptal and centrilobar emphysema (14% emphysema) and basal ﬁbrosis. (C) Triple match in small airways disease. Severely abnormal
V/Q SPECT/CT with multiple matched patchy ventilation and perfusion defects and matching with areas of mosaic perfusion on low-dose CT
in subject with severe airway obstruction, hyperinﬂation, and reduced diffusion capacity due to bronchiolitis obliterans. HRCT shows extensive
areas with low attenuation and mosaic “perfusion” and extensive air-trapping compatible with bronchiolitis obliterans, but no emphysema. (D)
Triple match in emphysema. Severely abnormal V/Q SPECT/CT with matched reduced ventilation and perfusion which is worst in the lower
part of the lungs matching with CT ﬁndings of emphysema (30% emphysema). Patient with severe airway obstruction, hyperinﬂation, and low
diffusion capacity due to emphysema and alpha-1 antitrypsin deﬁciency. Left 3 images—transaxial projections. Right 3 images—coronal pro-
jections. Left: ventilation (81mKr); mid: perfusion; right: low-dose CT. COPD, chronic obstructive pulmonary disease; HRCT, High-resolution
CT; V/Q, ventilation-perfusion.
18 J. Mortensen and R.M.G. Bergwith evidence of inﬂammation and airspace enlargement on
histology, notably the small airways.24 Since these changes
are reversed by the cessation of tobacco-smoke exposure,25
they likely reﬂect changes that also occur during the very
early stages of COPD in the clinical setting. This may be
detected as an inhomogeneous distribution of ventilation, as
reported using ventilation SPECT in otherwise healthy smok-
ers with normal spirometry.19 While spirometry is not a sen-
sitive measure of small airway function, studies that compare
the results of V/Q SPECT to more speciﬁc and sensitive tests
of small airway function, such as impulse oscillometry and
multiple breath N2 washout, are warranted, particularly in
patients with early or mild COPD. Apart from ventilation
inhomogeneity, such studies should also focus speciﬁcally
on perfusion and V/Q ratio distribution patterns.Ventilation and Perfusion
Scintigraphy in Lung Volume
Reduction
In end-stage COPD, lung volume reduction using surgery or
endoscopic treatments with one-way valves or coils may be
used therapeutically to reduce the extent of emphysematous
hyperinﬂation. This both improves the elastic recoil of the
lungs and pulmonary gas exchange while also reducing dys-
pnea by shifting volume, ventilation, and perfusion from the
most afﬂicted emphysematic lung lobes to better functioning
areas. Both V/Q scintigraphy and CT are used to select eligi-
ble patients for the speciﬁc treatments, and are furthermore
useful for identifying the most diseased target areas in the
lungs and to assess treatment effects (Fig. 4).26
Figure 2 Ventilation SPECT/CT with simultaneous acquisition of
Technegas and 81mKr-gas in a patient with severe COPD with
emphysema. The krypton gas has a much more peripheral penetra-
tion and more homogenous distribution compared to Technegas,
which shows several hot spots in the central airways. The ventila-
tion is severely impaired in the lower lobes that are hyperinﬂated
on CT. Patient has alpha-1 antitrypsin deﬁciency. Upper row—
transaxial. Second row—coronal. Third row—saggital. Left: Tech-
negas; left-mid: 81mKr; center: low-dose CT; right-mid: fused Tech-
negas/CT; right: fused 81mKr/CT. COPD, chronic obstructive
pulmonary disease; HRCT, High-resolution CT; V/Q, ventilation-
perfusion.
Figure 3 V/Q SPECT/CT showing the stripe-sign in a patient with
severe COPD with emphysema. Both ventilation and perfusion is
primarily localized in the periphery (stripe-sign) with severe reduc-
tion in central parts of the lobes corresponding to centrilobular
Lung Scintigraphy in COPD 19emphysema on HRCT (28% emphysema). Upper row—transaxial.
Second row—coronal. Third row—saggital. Lower row: density
map histogram and image of HRCT with emphysema marked
red. Left: ventilation (81mKr); mid: perfusion; right: low-dose
CT. COPD, chronic obstructive pulmonary disease; HRCT, High-
resolution CT; V/Q, ventilation-perfusion.A study showed that information obtained from planar per-
fusion scintigraphy combined with CT was superior to a CT-
based assessment alone for determining the extent and distri-
bution of emphysema prior to surgical lung volume reduc-
tion.27 The ability of planar V/Q scintigraphy (using 81mKr as
the ventilation tracer) to predict outcome after lung volume
reduction surgery was assessed in a prospective study on 50
patients with severe emphysema.28 Both measures of ventila-
tion and perfusion inhomogeneity predicted the postsurgical
improvement in lung function evaluated by spirometry, and
could furthermore largely explain why greater improvements
were observed in patients with centrilobular than panlobular
emphysema, as determined histopathologically in the
resected specimens.28
The predictive impact of presurgical perfusion scintigra-
phy in relation to lung volume reduction surgery has been
addressed in one retrospective study.29 Both planar and
SPECT perfusion scans were visually analyzed on a four-
point scale in upper and lower lung zones to provide a spe-
ciﬁc perfusion index. This correlated to spirometry ﬁndings
3-12 months after surgery, and the results did not differ
between planar imaging and SPECT, most probably because
of the rather crude lung zones used. Hence, more advanced
analyses, including a semiautomatic lobar analysis of V/Q
SPECT/CT compared before and half year after treatment
with endobronchial one-way valves showed signiﬁcant
reductions in perfusion, ventilation and volume of the
treated lobes, and signiﬁcant increases in the ipsilateral non-
targeted lobes, but no changes in the contralateral lung.30 In
contrast, no changes were found using a crude 3-zone
(upper, mid, lower) analysis of planar V/Q imaging, even
though the intraobserver coefﬁcient of variation for assessment
of lobar target ventilation and perfusion was below 1% in planar
analysis, and below 3% in SPECT/CT analysis.The combination of CT and scintigraphy is thus useful for assess-
ing patient eligibility, for identifying target zones, and for follow-
up in the context of lung volume reduction treatment. However,
the added value from using SPECT or SPECT/CT rather planar
imaging, as well as from performing V/Q scintigraphy rather than
a perfusion scan alone, remains to be clariﬁed.Lung Scintigraphy,
Comorbidities, and
Complications of COPD
COPD patients have a high risk of serious complications and
comorbidities such as exacerbations, pneumonia, pulmonary
embolism, lung cancer, and cardiac failure. In addition to
any COPD-related changes in ventilation and perfusion,
these conditions may give rise to different characteristic pat-
terns on V/Q SPECT.31 In this context, adding a low-dose
CT to a V/Q SPECT protocol is particularly useful. This
approach was evaluated prospectively in stable COPD
patients and healthy smokers,32 in which the low-dose CT
was found to make the V/Q SPECT interpretation more cer-
tain in 10% of the cases, while also providing additional
diagnoses such as lung cancer, emphysema, pulmonary
embolism, and heart failure, in the majority of cases. Hence,
V/Q SPECT/CT has an added value compared to performing
V/Q SPECT in COPD patients.
Figure 4 V/Q SPECT/CT in a patient with severe COPD with emphy-
sema before and after lung volume reduction surgery. Severe reduction
of ventilation and perfusion in the upper part of right lung correspond-
ing to centrilobular emphysema seen on HRCT. After lung volume
reduction surgery of the right upper lobe, ventilation, and perfusion
improves in the right lung which also is less hyperinﬂated. Left: fused
ventilation (81mKr)/CT; mid: fused perfusion/CT. Right: HRCT with red
marking of emphysema (47% emphysema; 62% in right and 20% in
left lung). COPD, chronic obstructive pulmonary disease; HRCT, High-
resolution CT; V/Q, ventilation-perfusion.
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V/Q scintigraphy is a valuable functional imaging biomarker
in relation to several aspects of COPD. Disturbances in the
distribution of ventilation and perfusion, which are pertinent
to the pathophysiology of COPD, are directly visualized, par-
ticularly when using inert gases or Technegas as ventilation
tracers while performing the scintigraphy as a SPECT. It is
well documented that speciﬁc changes on V/Q scintigraphy
reﬂect disease severity in COPD, and furthermore provide
information on the extent and distribution of disease in the
lungs. It is therefore important in the workup of lung volume
reduction treatment, and when combined with low-dose CT
it may furthermore add important information on complica-
tions and comorbidities of COPD. The high sensitivity of
V/Q scintigraphy, particularly SPECT, may unveil very early
and/or mild changes of COPD in the small airways and pul-
monary vascular function that cannot be detected by spirom-
etry or HRCT, but more clinical studies are warranted to
determine its potential for the early detection of COPD.References
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